Vividion Therapeutics Company

Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.
Technology: Drugs
Industry: Geroscience
Headquarters: United States
Founded Date: 2013-01-01
Employees Number: 51-100
Funding Status: Early Stage Venture
Investors Number: 12
Total Funding: $236.5M
Estimated Revenue: $50M to $100M
Last Funding Type: Series B

Visit Website
information@vividion.com
https://twitter.com/vividionrx
Register and Claim Ownership